**Supplementary Table S6.** AE summary in SAS

|  |  |  |
| --- | --- | --- |
|  | TMF group (n=95) | Blank control group (n=101) |
| Any grade | Grade ≥3  | Any grade | Grade ≥3  |
| TEAE, n (%) | 75 (78.9) | 2 (2.1) | 54 (53.4) | 1 (1.0) |
| TRAE, n (%) | 20 (21.1) | 1 (1.1) | 1 (1.0) | 0 |
| TEAEs leading to discontinuation | 1 (1.1) | 0 | 0 | 0 |
| TRAEs leading to discontinuation | 1 (1.1) | 0 | 0 | 0 |
| TEAEs leading to dose reduction | 0 | 0 | 0 | 0 |
| TRAEs leading to dose reduction | 0 | 0 | 0 | 0 |
| TEAEs leading to treatment suspension | 10 (10.5) | 1 (1.1) | 0 | 0 |
| TRAEs leading to treatment suspension | 4 (4.2) | 1 (1.1) | 0 | 0 |
| TEAEs leading to withdrawal | 2 (2.1) | 1 (1.1) | 1 (1.0) | 0 |
| TRAEs leading to withdrawal | 2 (2.1) | 1 (1.1) | 0 | 0 |
| TEAEs leading to death | 0 | 0 | 0 | 0 |
| TRAEs leading to death | 0 | 0 | 0 | 0 |
| SAE | 2 (2.1) | 2 (2.1) | 1 (1.0) | 1 (1.0) |
| Treatment-related SAEs | 1 (1.1) | 1 (1.1) | 0 | 0 |

TMF, tenofovir amibufenamide; TEAE: treatment-emergent adverse event; TRAE: treatment-related adverse event; SAE: serious adverse event.